Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 3/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17101672 | 0.86 | MMP1 (0.57) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL1404146 | 0.81 | KLK7 (0.38) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL28023347 | 0.79 | SMN1; SMN2 (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL5907629 | 0.77 | TSHR (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL9268142 | 0.77 | MMP1 (0.45) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL27701925 | 0.75 | TSHR (0.41) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL9065289 | 0.75 | ALDH1A1 (0.46) | SMN1; SMN2MAPTACE | |
| SCHEMBL18668788 | 0.75 | SMN1; SMN2 (0.37) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL9219486 | 0.74 | CA1 (0.39) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL15945368 | 0.74 | CYP1A2 (0.41) | MMP1MMP2MMP3MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051461-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR, William C. (US) | 2000-11-15 | — | — | EP | claimed |
| WO-1999066009-A2 | FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE | ORR WILLIAM C (US) | 1999-12-23 | — | — | WO | claimed |
| EP-4595775-A2 | BHB-CITRATE COMBINATION PRODUCTS FOR RENAL HEALTH AND TREATING DISEASE | The Regents of the University of California (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240000735-A1 | Compositions and Methods for Dietary Management | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-04 | — | — | US | disclosed |
| WO-2022173813-A1 | IMPROVED BHB-CITRATE FORMULATIONS FOR PROMOTING HEALTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-18 | — | — | WO | disclosed |
| CN-114144174-A | Methods and compositions for supporting kidney health | 加利福尼亚大学董事会 | 2022-03-04 | — | — | CN | disclosed |
| EP-3937920-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING RENAL HEALTH | The Regents of the University of California (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210244694-A1 | BHB-Citrate Combination Products for Renal Health and Treating Disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210244695-A1 | Methods and Compositions for Supporting Renal Health | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-12 | — | — | US | disclosed |
| US-11013705-B2 | Methods and compositions for supporting renal health | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200289444-A1 | Methods and Compositions for Supporting Renal Health | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2020186154-A1 | METHODS AND COMPOSITIONS FOR SUPPORTING RENAL HEALTH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289444-A1 | Methods and Compositions for Supporting Renal Health | PKD2, GPR119, PKD1 | MMP1 4010/4885MMP2 4784/4885MMP3 3721/4885 |
| US-20240000735-A1 | Compositions and Methods for Dietary Management | PKD2, PKD1, GPR39 | MMP1 4165/4885MMP2 4857/4885MMP3 4434/4885 |
| US-11013705-B2 | Methods and compositions for supporting renal health | PKD2, GPR119, PKD1 | MMP1 4010/4885MMP2 4784/4885MMP3 3721/4885 |
| US-20210244694-A1 | BHB-Citrate Combination Products for Renal Health and Treating Disease | PKD2, PKD1, GPR119 | MMP1 4351/4885MMP2 4838/4885MMP3 4349/4885 |
| US-20210244695-A1 | Methods and Compositions for Supporting Renal Health | PKD2, GPR119, PKD1 | MMP1 4010/4885MMP2 4784/4885MMP3 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.